Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction

Trial Profile

Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Prasugrel (Primary) ; Ticagrelor (Primary)
  • Indications Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms PRAGUE-18
  • Most Recent Events

    • 10 Aug 2017 Status changed from discontinued to completed.
    • 30 Aug 2016 Status changed from active, no longer recruiting to discontinued for futility reason but the total follow-up will be 1 year for all patients and will be completed in 2017., as per an article published in the Circulation.
    • 30 Aug 2016 Primary endpoint has not been met. (Composite primary outcome measure consisting of Death / Re-infarction / Stroke / Serious bleeding requiring transfusion or prolonged hospitalization / Urgent Target Vessel Revascularization.), as per an article published in the Circulation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top